Here are the 10-K annual reports from Surrozen, Inc. (SRZN) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow SRZN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SRZN filings page.
Surrozen, Inc. files its annual report describing a shift to an ophthalmology-focused pipeline built on Wnt-pathway modulation. The company highlights preclinical eye candidates SZN-8141 and SZN-8143 for diabetic macular edema, wet age-related macular degeneration and uveitic macular edema, all based on its SWAP antibody platform.
Surrozen’s Fzd4-targeted antibody SZN-413 is partnered with Boehringer Ingelheim; Boehringer’s 2024 advancement decision triggered a $10.0 million milestone, and a 2026 toxicology milestone entitles Surrozen to an additional $5.0 million. The company also discontinued liver candidate SZN-043 in severe alcohol-associated hepatitis to focus resources on eye diseases.